Introduction {#sec1_1}
============

Cognitive impairment is common among elderly people. The most disabling form of cognitive impairment is dementia. Dementia may be caused by several diseases; however, Alzheimer disease (AD) is the predominant cause \[[@B1], [@B2]\]. Although only symptomatic treatment is currently available, it is important to identify those patients affected by cognitive impairment due to AD and it is equally important to make an early diagnosis to initiate timely treatment, when neuronal damage may still be limited \[[@B3], [@B4]\]. This issue becomes even more relevant when potentially disease modifying drugs will be introduced. Mild cognitive impairment (MCI) can be regarded as a risk state for dementia or in some cases as a prodromal stage of a dementia disease, especially AD \[[@B5]\]. It has been reported that 40--60% of patients with MCI develop AD within 5 years and even 10--15% of patients with MCI develop AD within 1 year \[[@B6], [@B7]\].

However, not every case of MCI will progress to dementia. MCI patients may remain cognitively stable or even reverse to normal cognition in time \[[@B8], [@B9], [@B10]\]. Currently, one way to differentiate between patients with MCI due to an underlying neurodegenerative disease and stable MCI patients is to continuously evaluate patients to detect whether they clinically progress to fulfill the criteria for dementia. Efforts are being made to determine early biomarkers of various dementia disorders, which exhibit a high diagnostic accuracy and reflect the biochemical and pathological hallmarks of the disease as well as being able to predict the conversion of MCI to AD \[[@B3], [@B11]\]. Various biomarkers, in particular imaging, for example, Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET) and Single Photon Emission CT methods, as well as cerebrospinal fluid (CSF) biomarkers have proven helpful in diagnosing AD and findings from biomarker analyses have even been incorporated in research criteria for AD \[[@B12]\]. However, these biomarkers may have limited usefulness, as some are expensive and may not be available outside academic centers, or are invasive and therefore may not be widely applied.

Electroencephalography (EEG) is an inexpensive method; it is simple to perform and available in most clinical settings \[[@B13], [@B14]\]. Furthermore, the method is noninvasive and thereby implies almost no physical discomfort for the patient. EEG records the electrical activity of cortical neurons and thus reflects the underlying brain function. EEG may thereby potentially be an important biomarker of disturbances in the cognitive function \[[@B15], [@B16]\]. As AD is a disease affecting the cerebral cortex, EEG abnormalities reflecting the structural and functional deficits in cortex due to the disease are frequently shown in AD \[[@B17]\]. Likewise, early EEG changes have been found in subcortical dementias, for example, Dementia with Lewy Bodies (DLB) and Parkinson Disease Dementia (PDD), which may separate DLB and PDD from both AD as well as healthy persons \[[@B18]\]. Currently, there is no clear evidence whether the use of conventional visual EEG analysis is exceeded by quantitative EEG (qEEG) analysis for diagnostic purposes \[[@B16]\].

QEEG is a computer-based analysis, which is independent of the subjective assessment seen in visual rated conventional EEG \[[@B19], [@B20]\]. Several studies have demonstrated a high diagnostic value of qEEG when evaluating patients with AD and MCI in the general population \[[@B17], [@B21], [@B22]\]. As EEG alterations may be present early in the course of the disease and even in the pre-clinical stage, qEEG may indeed be diagnostically and prognostically valuable in patients with MCI \[[@B22], [@B23], [@B24], [@B25], [@B26]\].

Statistical pattern recognition (SPR) is a data-analytic method used in qEEG. The SPR analyses in this study are based on the Icelandic database described in previous publications \[[@B18], [@B27]\], and therefore differs from publications evaluating EEG in dementia and MCI in a more traditional way.

The method has been found valuable in the diagnostic work-up of patients with cognitive impairment \[[@B18], [@B19], [@B27]\]. In particular, SPR discriminated excellently between LBD/PDD and healthy controls (HC) as well as other dementia disorders, but it also exhibited a good discriminative ability between HC and individuals with dementia. However, the diagnostic value of the SRP method in patients with MCI is more uncertain, as conflicting results have been reported \[[@B18], [@B27], [@B28]\]. In addition, the prognostic value of the SPR method in a consecutively referred heterogeneous cohort of patients with MCI in a memory clinic setting has not yet been established.

In the present study, the aim was to assess the potential value of the method as a prognostic indicator in a group of patients diagnosed with MCI and to investigate possible associations between the SPR analysis and the CSF biomarker analysis. Furthermore, we aimed to investigate the ability of the SRP method to differentiate between patients with MCI, mild AD and HC compared to the diagnostic ability of the conventional visual EEG analysis.

Materials and Methods {#sec1_2}
=====================

Study Population {#sec2_1}
----------------

The study is a subgroup study of a larger prospective multicenter cohort study, conducted at 5 Nordic memory clinics located at the Zealand University Hospital in Roskilde and University Hospital Copenhagen, Rigshospitalet in Copenhagen (Denmark), the Deaconess Hospital in Bergen and the Oslo University Hospital (Norway), and the Karolinska University Hospital Huddinge in Stockholm (Sweden).

Patients, aged 50--85 years consecutively referred for cognitive evaluation and diagnosed with either MCI or mild AD (baseline Mini-Mental State Examination \[MMSE\] score of 22 or above) from May 2011 to December 2014 were eligible for inclusion. In this sub-study of the NORDEEG cohort, we included only subjects in whom lumbar puncture with examination of the CSF biomarkers AB42, total tau (T-Tau) and phosphorylated tau (P-tau), had been carried out as part of the standardized clinical diagnostic work-up.

Common standards for the diagnostic work-up were followed in all 5 hospitals. At the time of referral, patients underwent a standardized diagnostic assessment including physical and neurological examination, clinical history from patient and relative, routine blood analysis, brain CT or MRI scan, lumbar puncture with CSF AD biomarker analysis as well as a cognitive screening by a MMSE. If patients remained diagnostically unresolved despite the standardized diagnostic assessment, a full neuropsychological evaluation was conducted by a neuropsychologist.

Patients with MCI were diagnosed according to the Winblad consensus criteria \[[@B29]\]. Patients with AD were diagnosed according to the DSM-IV-R and the NINCDS-ADRDA for AD \[[@B12], [@B30]\].

The general rule for the NORDEEG cohort was that either the diagnoses were settled at a consensus conference by an experienced multidisciplinary team or as a minimum in consensus between at least 2 experienced physicians (specialist level) in the field of dementia, based on all available examination results, but independently ("blind") of the EEG results. Participants were only referred for a standardized EEG, if they had consented to participate in the study.

Patients were excluded if they did not give informed consent to participate or if they were affected by other neurological, physical or severe psychiatric disease. Patients, who also were diagnosed with mild anxiety or depression were included, as these conditions often are seen concurrently in patients with MCI and mild dementia. Patients were also excluded if they were found to use sedative medication (e.g., Morphine, Benzodiazepine on a regular basis), which could give rise to cognitive impairment.

Patients were clinically evaluated yearly on an ongoing basis as a part of the normal clinical routine in the memory clinics and diagnoses were reevaluated and based on clinical progression, the diagnoses were subsequently revised by experienced physicians.

As the study is a naturalistic study, in which patients are recruited and clinically followed as a part of everyday clinical practice, the length of the follow-up period varied due to differences in the clinical set-ups, due to differences in patients\' ongoing ability to perform cognitive testing as well as unexpected dropouts.

The HC were volunteers aged 50--85 years recruited for scientific research through public invitations at the memory clinics, at local associations for elderly and through an online recruitment site for trail subjects. Exclusion criteria were presence of memory complaints or other cognitive symptoms as well as signs of major neurological, psychiatric, or physical disease, which potentially could elicit cognitive impairments. Furthermore, they could not receive sedatives (Morphine and Benzodiazepine) on a regular basis. The HC all underwent the previously described standardized diagnostic assessment as the patients, including EEG, in either the memory clinic at Zealand University Hospital or at University Hospital Copenhagen, Rigshospitalet (Denmark) at inclusion. Follow-up visits were carried out on a yearly basis for 3 years, where all HC had serial cognitive screening.

The investigator, who performed the follow-up visits, was blinded to the results of EEG and CSF analysis.

Electroencephalogram {#sec2_2}
--------------------

EEG registrations were performed at all 5 clinics according to a common harmonized instruction. The EEG recording and feature extraction are comprehensively described by Engedal et al. \[[@B27]\]. EEG data were analyzed by the SPR technique based on a dementia database developed by MentisCura \[[@B31]\].

In essence, the SPR technique compares EEG recordings with normative data from a database containing EEG recordings from more than 1,000 patients with dementia disorders as well as approximately 500 HC. By comparing features from 2 diagnostic groups of EEGs, a classifier is constructed. When an individual EEG recording is analyzed according to the classifiers, it yields an index for each classifier with a value between 0 and 1. The index values represent the likeliness of the individual EEG to be indistinguishable from either one of the diagnostic groups. If the value is close to 0 subsequently to 1, the EEG is indistinguishable from EEGs in one of the diagnostic groups in question \[[@B18], [@B28]\]. Five classifiers from a previous study were used in the present study (Box 1; Fig. [1](#F1){ref-type="fig"}) \[[@B18]\]. Subsequently, all EEGs were evaluated at each participating clinic by one certified medical doctor and classified on the basis of the index values of each classifier produced by the SPR technique. This evaluation was performed without knowledge of the clinical diagnosis. A final EEG based diagnosis was established if there was consensus among the certified medical doctors at each participating clinics with regard to the classification of the individual EEG among the participating clinics. In a fraction of the qEEGs, it was not possible to classify the pattern according to one of the 4 previously defined classifiers. These were combined in a group with an "inconclusive" qEEG pattern.

To evaluate the diagnostic and prognostic value of the SPR method regardless of the specific qEEG diagnosis, we used the individual qEEG diagnoses to separate the qEEGs into 2 categories. A stable category, which embraced patients with non-progressive qEEG patterns classified as "Normal," and "MCI" and a progressive category embracing patients with progressive qEEG patterns classified as "AD" and "DLB/PDD."

Visual EEG Assessment {#sec2_3}
---------------------

In addition to the SPR analysis, visual EEG assessments were also performed to register focal abnormalities as well as paroxysmal alterations. The EEG recordings were assessed by 1 of 2 experienced neurophysiologists (MDA and TWK). At the time of the assessment, they did not have any knowledge of diagnosis and other clinical information.

CSF Analysis {#sec2_4}
------------

Lumbar puncture was performed at all 5 clinics. Methods for collection and analysis are well described by Ferreira et al. \[[@B32]\]. Levels of CSF Amyloid (Aβ~42~), T-tau and P-tau were analyzed and regarded as markers of amyloid accumulation subsequent neurodegeneration.

Ethics {#sec2_5}
------

The study was reported and approved by the Data Protection Agency Authorities and by the Regional Ethical Committees in each of the participating countries. All participants signed an informed consent form prior to participation.

Statistics {#sec2_6}
----------

Kruskall-Wallis test and Mann-Whitney U test were used for median comparisons between groups subsequent for pairwise comparisons. The chi-square test was used for nominal variables. To correct for analysis with multiple comparisons, results were considered statistically significant when *p* values were *p* \< 0.01. Receiver Operating Characteristic (ROC) curves of the qEEG diagnosis, qEEG categories and the visual EEG analysis were drawn as a plot of the true positive value (sensitivity) against the false positive value (1 - specificity) for different possible cutoff values of the respective markers. The ROC curves illustrate the ability of each parameter to (1) separate both the HC from the cognitive impaired patients as well as separate MCI from AD and (2) separate the progressive versus the stable MCI patients. The area under the curve (AUC) was calculated as a measure of the parameter\'s overall accuracy. Gamma correlations were used to study relations between variables.

Statistical analysis was carried out using SPSS version 22 and "R" environment for statistical computing, version 3.1.2.

Results {#sec1_3}
=======

A total of 129 participants were included in our study. At baseline, 56 were diagnosed with MCI, 32 were diagnosed with mild AD, and 41 were enrolled as HC. Clinical data are presented in Table [1](#T1){ref-type="table"}.

Apart from expected differences in cognitive function and biomarker status, a significant difference in comorbidity between the groups was found, as 25% in the MCI group were affected by depression or anxiety compared to 18.8% in the AD group and only 4.9% in the HC group. A total of 90% of the patients with a final consensus diagnosis of AD had 1 or more abnormal CSF biomarkers, while 65% of the clinical MCI group and 24% of the HC group had one or more abnormal CSF biomarkers.

The qEEG diagnoses and the qEEG categories distributed by clinical diagnosis are shown in Table [2](#T2){ref-type="table"}. In the HC group, a remarkable low percentage of approximately 15% had a qEEG diagnosis of "normal" while 31.7% had a SPR-EEG diagnosis of "AD" and 24.4% were "inconclusive." Significantly more patients diagnosed with AD had a progressive qEEG pattern at baseline than MCI patients and HC respectively (Table [3](#T3){ref-type="table"}). On the contrary, only 9.4% in the AD group had a stable qEEG pattern compared to 37.5 and 41.5% in the MCI group and HC respectively. The diagnostic accuracy of the SPR method to discriminate between MCI and HC respectively AD as well as between AD and HC was illustrated by ROC curve analysis (Table [4](#T4){ref-type="table"}).

A subgroup of 84 participants had data on the visual analysis of the conventional EEG available (Table [2](#T2){ref-type="table"}). Interestingly, by visual inspection, 28% of the MCI patients exhibited focal abnormalities compared to only 5 and 2.6% in the AD patients and HC respectively (*p* \< 0.01, Cramer\'s V = 0.375). No participants exhibited paroxysmal abnormalities at their baseline EEG recording (Table [2](#T2){ref-type="table"}). ROC curve analyses were also constructed to illustrate the diagnostic accuracy of the visual EEG analyses compared to the SPR method in the subgroup (Table [4](#T4){ref-type="table"}).

Prognostic Value of the SPR Method in MCI {#sec2_7}
-----------------------------------------

During the follow-up period, 23 (41.1%) participants with MCI clinically progressed to fulfill the diagnostic criteria for dementia. In this group of progressive MCI patients, 1 participant was diagnosed with Lewy Body dementia, 1 participant was diagnosed with corticobasal degeneration, and the remaining 21 participants were diagnosed with AD. Twenty-one participants (37.5%) with MCI remained stable and the remaining 12 participants (21.4%) were lost to follow-up. Clinical data are presented in Table [3](#T3){ref-type="table"}.

No significant difference in cognitive status, that is, MMSE score, or in CSF AD biomarkers between the stable and progressive groups was seen. At baseline no significant differences in qEEG categories between the clinical stable and progressive MCI groups was found.

ROC curves analysis revealed no predictive ability with regard to predicting future clinical progression in our group of MCI patients with an AUC value for qEEG diagnosis of 0.58 respectively an AUC value for qEEG categories of 0.55.

Correlations between the SPR Method and Cognitive Tests as Well as CSF AD Biomarkers {#sec2_8}
------------------------------------------------------------------------------------

In the entire cohort, a moderate negative correlation between the SRP-EEG diagnosis as well as the qEEG categories and both the baseline MMSE score and CSF Amyloid was found. In addition, a moderate positive correlation between the qEEG diagnosis as well as the qEEG categories and CSF T-tau respectively CSF P-tau levels were found (Table [4](#T4){ref-type="table"}).

Discussion {#sec1_4}
==========

Our findings with regard to a low diagnostic and prognostic ability of the SPR method in a typical clinical setting were unexpected, given the fact that previous studies showed more promising results \[[@B18], [@B27], [@B32], [@B33]\].

The diagnostic and prognostic use of qEEG in the diagnostic assessment of patients with cognitive impairment has gained much attention. In particular, the ability of qEEG to diagnose dementia disorders in the very early phase of the disease, even in the pre-dementia phase, where the patients only fulfill the criteria of MCI, has been an area of interest.

Previous studies have demonstrated an excellent to good discriminative ability of the SPR based on the Islandic dementia database in separating AD from HC \[[@B18], [@B27], [@B28]\]. Nevertheless, conflicting results have been reported as Ommundsen et al. \[[@B19]\] found the method to exhibit a somewhat lower ability to diagnose AD in patients referred to a memory clinic.

Likewise, Snaedal et al. \[[@B18]\] found the SPR method to separate AD from stable MCI with an accuracy of 80% indicating that the stable MCI patients exhibit an EEG pattern quite different from AD. However, this could not be replicated in a more recent study by Engedal et al. \[[@B27]\].

The low differential diagnostic ability of the method in our study was unexpected regarding these more favorable results. We find no critical differences in the methodology used in the present study and in previous studies to explain this, although the SPR classifiers may have been slightly different. For a full technical description of the applied SPR method and the selection of qEEG classifiers, please see reference \[[@B18]\].

However, it may be contributed to the low specificity of the SPR to identify the healthy subjects in our study population. The method did only classify 14.6% of the HC as having a "normal" qEEG pattern, whereas 34.1% were classified as having a progressive qEEG pattern, that is, an AD or DLB/PDD qEEG pattern and 24.4% had an inconclusive qEEG pattern (Table [2](#T2){ref-type="table"}).

Therefore, one may wonder whether our group of HC was not comparable with the HC group used to create the database. However, there were no differences in the age range between the 2 groups. Likewise, we find no evidence of our HC group being less healthy than the HC group in the database, as our HC group underwent a rather comprehensive diagnostic assessment including multiple cognitive testing and CT or MRI scan as well as a lumbar puncture with CSF AD biomarker analysis and an amyloid PET scan in the majority of the subjects. During the baseline assessment, we found only 2 healthy subjects, who had signs of cerebral amyloid (one had low CSF amyloid level and one had a positive amyloid PET scan but a normal CSF amyloid level). However, both were without any cognitive complaints and performed in the normal range on all cognitive tests. The influence of differences in mental comorbidity cannot be ruled out, as it may affect the EEG patterns, causing an inconclusive EEG pattern. Otherwise, the low discriminative ability found in our study population cannot be explained.

Nevertheless, the SPR method exhibited a moderate to good sensitivity as 71.9% of all AD patients were classified correctly as having a progressive qEEG pattern.

In accordance with the study by Engedal et al. \[[@B27]\] and Ommundsen et al. \[[@B19]\], we found the SPR method to separate patients with AD from MCI to be not so effective, thereby indicating that a proportion of the MCI patients may actually be affected by AD in the early stage. The somewhat higher discriminative ability in separating AD from MCI found by Snaedal et al. \[[@B18]\] may partly be due by the fact that they only included MCI patients, who prior to inclusion had remained clinical stable for a minimum of 2 years.

As the SPR method failed to discriminate between HC and patients with both MCI and AD in our population, we hypothesized that a standardized visual analysis of a conventional EEG may potentially have a similar or superior diagnostic accuracy. It is well known that signs of diffuse slow EEG rhythms is useful in separating HC from AD \[[@B34], [@B35]\], but the value of focal EEG alterations in cognitively impaired is not clear \[[@B36]\]. Liedorp et al. \[[@B36]\] found that focal abnormalities without diffuse alterations were associated with MCI, whereas the combination of focal and diffuse alterations argued against the MCI diagnosis. This is in line with the finding by Visser et al. \[[@B37]\] that focal EEG changes in healthy persons may be an early sign of cognitive dysfunction.

Our findings were supportive of the previous studies, as we found a significant higher percentage of focal EEG abnormalities in the MCI group than in the group of AD patients and HC (Table [2](#T2){ref-type="table"}). Nevertheless, ROC analysis revealed that the visual assessment of EEG performed poorly in discriminating the groups, and worse than the computerized analysis (qEEG).

Specific EEG alterations may potentially be predictive of future clinical progression in MCI patients to fulfill the diagnostic criteria of AD \[[@B17], [@B22], [@B24], [@B38]\]. These EEG alterations may resemble the EEG abnormalities typically found in AD, for example, an increase in theta and delta activities as well as a decrease in alpha and beta activities \[[@B17]\]. In a pilot study, Snaedal et al. \[[@B28]\] demonstrated a potential ability of the SPR method in predicting clinical progression to AD in a group of MCI patients Likewise, a recent Italian study of MCI patients showed that qEEG may predict future clinical development of LBD \[[@B26]\]. In contrast, others have not detected EEG alterations, which could differentiate between the progressive and the stable MCI patients \[[@B24], [@B25]\].

In our study, the distributions of patients with stable and progressive qEEG patterns were very similar in the clinical stable and progressive group of MCI patients (Table [3](#T3){ref-type="table"}). Hence, ROC curve analyses demonstrated a low predictive ability of future clinical progression in MCI in our study.

This finding is in contrast with previous findings by Snaedal et al. \[[@B18]\]. The conflicting results may partly be explained by differences in study populations as Snaedal et al. \[[@B18]\] exclusively compared AD with MCI patients remaining stable for 2 years or more, while we embraced all patients diagnosed with MCI at baseline. As the rate of cognitive decline and clinical progression in dementia disorders varies, this might in our study imply inclusion of patients in the stable MCI group, who in fact are affected by AD in the prodromal stage and hence in time will progress to a dementia disorder. This could explain the high percentage of stable MCI patients exhibiting a progressive qEEG pattern at baseline. Supporting this is the finding that there are no significant group differences in the CSF AD biomarker levels at baseline between the progressive and stable MCI patients (Tables [3](#T3){ref-type="table"}, [5](#T5){ref-type="table"}), as correlations between CSF AD biomarkers and EEG alterations have been demonstrated both within our study as well as in others \[[@B39]\].

Strengths {#sec2_9}
---------

Our study has several strengths. First, it was conducted in a memory clinic setting using a consecutively recruited population. All patients were examined in a standardized manner according to harmonized protocol used by all participating clinics. The patients were followed prospectively, which eliminated biases from retrospective information gathering. Fur thermore, all EEG recordings were visually analyzed by 1 of 2 experienced neurophysiologists, which minimized interrater variability. Finally, the EEG recordings were not part of the diagnostic assessment, thereby reducing the risk of circularity.

Limitations {#sec2_10}
-----------

The fairly small sample size of this study is a limitation. The findings of low predictive ability of the SPR method with regard to progression may as a consequence be due to lack of statistical power. Likewise, the variability in the length of the follow-up period was large, which may have influenced the predictive value of the SPR method. In particular, this is an issue with regard to the group of stable MCI patients as it is well known that time to conversion varies and it is therefore likely that some patients labeled stable at the end of our study, will eventually progress. Finally, we cannot rule out that some patients may have been diagnosed incorrectly, as the cohort lacks postmortem diagnostic confirmation. To address this, the clinical diagnosis was established by at least 2 experienced physicians or by a multidisciplinary team at each clinic.

Conclusion {#sec1_5}
==========

In conclusion, we found the overall diagnostic ability of the SPR method to be low in our consecutively referred cohort. The method exhibited the highest discriminative ability in separating AD from HC. Nevertheless, it was still lower than reported in other studies. We did find the SPR method to be superior to the conventional visual EEG analysis in discriminating between both the HC and all groups of the cognitively impaired patients. The low ability of the SPR method to predict future clinical progression in patients with MCI in our cohort was unexpected as previous studies have indicated more promising results. Further prospective studies on the utility of the SPR method for predicting clinical progression in a consecutively referred cohort in a normal clinical setting are needed.
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###### 

Characteristics of the study population baseline

  Total study population                           HC                      MCI                     AD
  ------------------------------------------------ ----------------------- ----------------------- --------------------------------------------------------
  *n* (%)                                          41 (31.8)               56 (43.4)               32 (24.8)
  Age, years                                       65.0 (62.0--71.5)       68.0 (64.0--74.0)       69.5 (64.5--75.6)
   Age, range                                      50--85                  58--82                  58--85
  Gender (M:F), %                                  53.7:46.3               53.6:46.4               68.75:31.25
  Education, years                                 13.0 (10.0--16.0)       12.0 (9.0--15.0)        10.5 (8.0--14.8)
  Follow-up, months                                35.0 (34.5--36.0)       22.0 (15.0--32.0)       15.0 (11.0--27.0)
  MMSE score[\*](#T1F1){ref-type="table-fn"}       29 (28--30)             28 (26--29)             25 (24--27)
  Comorbidity, %[\*](#T1F1){ref-type="table-fn"}   4.9                     25.0                    18.8
  CSF Amyloid                                      916.0 (805.0--1166.0)   715.0 (563.0--1037.0)   574.5 (374.0--668.0)[\*\*](#T1F2){ref-type="table-fn"}
  CSF P-tau                                        47.0 (35.0--64.0)       58.0 (39--74.0)         84.0 (70.5--94.8)[\*\*](#T1F2){ref-type="table-fn"}
  CSF T-tau                                        275.0 (191.0--346.0)    394.0 (223.5--542.5)    556.5 (470.0--893.8)[\*\*](#T1F2){ref-type="table-fn"}

Data are expressed as medians (IQRs), significant when *p* \< 0.01, due to multiple comparisons. Comorbidity covers depression or anxiety.

Significant, when all groups are compared individually.

Significant, when compared to HC and MCI.

MMSE, mini-mental state examination; CSF, cerebrospinal fluid; P-tau, phosphorylated tau protein; T-tau, total tau protein; MCI, mild cognitive impairment, AD, Alzheimer disease.

###### 

qEEG characteristics in the study population

                                                             HC          MCI         AD
  ---------------------------------------------------------- ----------- ----------- -------------------------------------------
  Total study population, *n*                                41          56          32
  qEEG diagnosis, *n* (%)                                                            
   Normal                                                    6 (14.6)    9 (16.1)    1 (3.1)
   MCI                                                       11 (26.8)   12 (21.4)   2 (6.3)
   AD                                                        13 (31.7)   22 (39.3)   22 (68.8)
   LBD/PPD                                                   1 (2.4)     3 (5.4)     1 (3.1)
   Inconclusive                                              10 (24.4)   10 (17.9)   6 (18.8)
  qEEG categories, *n* (%)[\*](#T2F1){ref-type="table-fn"}                           
   Stable                                                    17 (41.5)   21 (37.5)   3 (9.4)[\*](#T2F1){ref-type="table-fn"}
   Progressive                                               14 (34.1)   25 (44.6)   23 (71.9)[\*](#T2F1){ref-type="table-fn"}
   Inconclusive                                              10 (24.4)   10 (17.9)   6 (18.8)

Stable qEEG pattern is comprised by qEEGs with normal, SCI and MCI patterns. Progressive qEEG pattern is comprised by qEEGs with AD and LBD patterns.

Significant, when compared to MCI and HC, *p* \< 0.05.

MCI, mild cognitive impairment; AD, Alzheimer\'s disease; HC, healthy control; LBD, Lewy Body Dementia; PDD, Parkinson Disease Dementia.

###### 

Characteristics of the MCI group

  Population characteristics           Clinical stable MCI    Clinical progressive MCI
  ------------------------------------ ---------------------- --------------------------
  *n* (%)                              21 (47.7)              23 (52.3)
  MMSE score                           28 (26--29)            27 (25--29)
  CSF Amyloid                          699.0 (549.0--998.5)   660.0 (468.5--913.5)
  CSF T-tau                            414.0 (244.0--607.0)   441.0 (327.0--601.5)
  CSF P-tau                            61.0 (39.0--88.5)      58.0 (45.5--74.0)
  Stable qEEG pattern, *n* (%)         6 (28.6)               6 (26.1)
  Progressive qEEG pattern, *n* (%)    10 (47.6)              13 (56.5)
  Inconclusive qEEG pattern, *n* (%)   5 (23.8)               4 (17.4)

Progressive qEEG pattern is comprised of qEEGs with AD and LBD patterns. Stable qEEG pattern is comprised of qEEGs with normal and MCI patterns.

###### 

ROC curves analysis of the qEEG diagnosis, qEEG categories, and the visual EEG analysis

  ----------------------------------------------------------------------------------------
  Group comparisons                   AUC\             AUC\              AUC\
                                      qEEG diagnosis   qEEG categories   Visual analysis
  ----------------------------------- ---------------- ----------------- -----------------
  Total study group                                                      

   MCI versus HC                      0.56             0.56              

   AD versus MCI                      0.60             0.61              

   AD versus HC                       0.66             0.66              

  Subgroup with visual EEG analysis                                      

  MCI versus HC                       0.67             0.64              0.63

  AD versus MCI                       0.54             0.58              0.36

  AD versus HC                        0.69             0.70              0.49
  ----------------------------------------------------------------------------------------

ROC, receiver operating characteristic; MCI, mild cognitive impairment; AD, Alzheimer\'s Disease; HC, healthy controls; AUC, area under the curve.

###### 

Correlations (gamma) between the SPR method and CSF AD biomarkers in the entire cohort

  Parameters    qEEG diagnosis              qEEG categories
  ------------- --------------------------- ---------------------------
  CSF amyloid   *r* = −0.254, *p* \< 0.01   *r* = −0.265, *p* \< 0.01
  CSF T-tau     *r* = 0.163, *p* \< 0.05    *r* = 0.167, *p* = 0.05
  CSF P-tau     *r* = 0.187, *p* \< 0.05    *r* = 0.209, *p* \< 0.05
  MMSE score    *r* = −0.210, *p* \< 0.05   *r* = −0.230, *p* \< 0.05

The qEEG diagnosis is defined as the individually qEEG diagnosis based on the result of the classifier analysis. The qEEG categories is based on the qEEG diagnosis and each group represent patients with qEEGs exhibiting either a stable qEEG pattern, a progressive qEEG pattern, or an inconclusive pattern.

MMSE, mini-mental state examination; CSF, cerebrospinal fluid; P-tau; phosphorylated tau protein; T-tau, total tau protein.
